McMullin M F, Hillmen P, Elder G E, Lappin T R, Luzzatto L
The Queen's University of Belfast, Northern Ireland.
Br J Haematol. 1996 Mar;92(4):815-7. doi: 10.1046/j.1365-2141.1996.421961.x.
In order to assess the rationale and possible indications for the use of recombinant erythropoietin in paroxysmal nocturnal haemoglobinuria (PNH), we have measured endogenous erythropoietin (Epo) levels in 18 patients with PNH and in 44 patients with iron deficiency anaemia (IDA). In both groups of patients we found a significant inverse correlation between Epo and haemoglobin (Hb). However, the mean Epo level was significantly higher in the PNH group (385 mU/ml) than in the IDA group (136 mU/ml). The range of Epo levels at any given Hb was greater in the PNH group than in the IDA group. There was a significant positive correlation between Epo and absolute reticulocyte count. Since Epo administration is unlikely to benefit patients with high levels of endogenous Epo, we conclude that in the majority of patients with PNH there is no indication for treatment with Epo.
为了评估在阵发性夜间血红蛋白尿（PNH）中使用重组促红细胞生成素的理论依据和可能的适应症，我们检测了18例PNH患者和44例缺铁性贫血（IDA）患者的内源性促红细胞生成素（Epo）水平。在两组患者中，我们均发现Epo与血红蛋白（Hb）之间存在显著的负相关。然而，PNH组的平均Epo水平（385 mU/ml）显著高于IDA组（136 mU/ml）。在任何给定的Hb水平下，PNH组的Epo水平范围都比IDA组更大。Epo与绝对网织红细胞计数之间存在显著的正相关。由于给予Epo不太可能使内源性Epo水平高的患者受益，我们得出结论，大多数PNH患者没有使用Epo治疗的指征。
